Background: Maintaining folate stability during sample handling is important, yet challenging.
Introduction
Suboptimal environmental conditions during preanalytical steps such as sample collection, processing, shipping, and storage can negatively affect analytical results. Knowledge about analyte stability during these steps is therefore critical. Serum folate is an important biomarker of folate status, and it has been measured as part of the U.S. NHANES for several decades (1) . Although the susceptibility of reduced folates to oxidative degradation is well known (2, 3) , only limited information is available on the behavior of serum folate forms during the full spectrum of preanalytical conditions. Hannisdal et al. (4, 5) have so far provided extensive information on the oxidative loss of 5-methyltetrahydrofolate (5-methylTHF) 4 , the major circulating portion of total folate (tFOL), to the pyrazino-s-triazine derivative of 4a-hydroxy-5-methylTHF [also known as MeFox (6) ] in a short-term (1 wk) kinetic study of serum and plasma exposed to room temperature (4) and in a long-term (up to 29 y) crosssectional study of serum frozen at a suboptimal (225°C) temperature (5) . Our group has provided information on a broad range of micronutrients, including serum tFOL measured by microbiologic assay, for 2 unfavorable preanalytical conditions that may be encountered in resource-limited situations: delayed processing of whole blood exposed to an elevated temperature sometimes encountered in the field (32°C) for up to 3 d and delayed freezing of serum exposed to a slightly cooled temperature achievable with cold packs (11°C) for up to 14 d (7) .
The main objective of the present study was to investigate the effects of a series of suboptimal preanalytical conditions on folate stability, covering the full spectrum from whole blood processing to repeated freeze/thaw cycles of samples as part of the laboratory analysis. Serum folate forms were measured with a sensitive and specific HPLC-tandem MS (HPLC-MS/MS) method (6, 8, 9) in a series of experiments: Expt. 1, delayed (#3 d) processing of freshly collected whole blood incubated at 32°C ; Expt. 2, delayed (#14 d) freezing of freshly obtained serum stored at 11°C; Expt. 3, short-term (#24 h) exposure of serum to elevated temperatures (room temperature and 37°C); Expts. 4 C 5 -labeled analogs were purchased from Merck Cie. All other reagents and solvents were of American Chemical Society grade (6, 8, 9) . We used in-house prepared quality control (QC) pools with the use of serum purchased from a U.S. blood bank. Other serum samples were from a CDC study that used volunteer blood collection (7) and from a large CDC study (convenience samples). Participants for both studies provided informed consent, and the study protocols were approved by the CDC Institutional Review Board and the CDC Research Ethics Review Board.
Sample processing for preanalytical experiments. All preanalytical experiments are described in Table 1 , and additional information on Expts. 1 and 2 was presented previously (7) . Folate calibrators for 5-methylTHF, folic acid, THF, 5-formylTHF, 5,10-methenylTHF, and MeFox and their respective 13 C 5 -labeled internal standards were prepared as described earlier (8, 9) . To measure serum folate forms, we processed samples by using an automated reversed-phase solid phase extraction method and analyzed sample extracts (all conditions from the same study participant in the same analysis) by HPLC-MS/MS (6). For Expts. 6 and 7 (conducted earlier), we used our previous HPLC-MS/MS method (8,9), which did not separate the 2 isobaric compounds MeFox and 5-formylTHF. Because we added 5-formylTHF in these serum QC pools at the time of pool preparation and used these specimens in those 2 experiments and we confirmed the target concentrations more recently with our updated HPLC-MS/MS method (which separates MeFox and 5-formylTHF via different mass transitions), we were able to subtract the correctly measured 5-formylTHF amount from the sum of MeFox and 5-formylTHF measured in Expts. 6 and 7 to obtain an estimate for MeFox. All sample processing steps were conducted under gold fluorescent lights.
To evaluate the quality of the analytical procedure, each analysis included 3 serum QC samples measured in duplicate, bracketing the unknown samples. We calculated serum tFOL as the sum of the individual folate forms including MeFox [by using an imputed value of limit of detection (LOD) divided by the square root of 2 for results less than the LOD]. We do not report results for the 2 minor folate forms 5-formylTHF and 5,10-methenylTHF because their concentrations were less than the LOD. We only report THF results in the text when concentrations were greater than the LOD.
Statistical analysis. Statistical analyses were performed by using SAS software (version 9.2; SAS Institute). We used a log 10 transformation to account for the right-skewed distributions and for the increasing variance with increasing folate concentration. We calculated leastsquares geometric mean concentrations by using back-transformation (95% CIs) for folate forms with the use of 1-factor (time) or 2-factor (time and pool) ANOVA, depending on the experiment ( Table 1) . As a consequence of the log transformation, differences relative to the reference condition were expressed as percentage changes of geometric means (95% CI) rather than an absolute difference in log-transformed values and evaluated for significance in pairwise comparisons by using a 2-sided level of a = 0.05. If the interaction between time and pool was significant (Expts. 3 and 6 for MeFox), we reported the percentage change results separately for each pool; otherwise, we reported the mean percentage change across the 3 pools. To facilitate the interpretation of molar changes in 5-methylTHF vs. MeFox, we also calculated the absolute change in geometric mean concentrations. Serum from promptly processed whole blood frozen at 270°C was used as a reference; statistical analysis was by 1-factor ANOVA. *0.0001 $ P , 0.05, **P , 0.0001. MeFox, pyrazino-s-triazine derivative of 4a-hydroxy-5-methyltetrahydrofolate; tFOL, total folate; 5-methylTHF, 5-methyltetrahydrofolate. 2 Values are geometric means (95% CIs); n = 21. 3 Values are percentage changes (95% CIs) compared with reference.
Serum folate stability 1875
Results
Expt. 1: delayed processing of whole blood. Freshly collected whole blood samples (n = 21) stored at 32°C for 1-3 d before processing showed substantial and significant decreases in serum tFOL (5.5-15.9 nmol/L, up to ;30%) and 5-methylTHF (14.5-25.1 nmol/L, up to ;60%) and increases in MeFox (7.17-8.63 nmol/L, up to ;400%) ( Table 2 , Supplemental Fig. 1A, B) . The gain in MeFox represented only a fraction of the loss in 5-methylTHF at either time point. Serum folic acid concentrations were stable under these conditions. Serum THF concentrations (0.647 nmol/L at baseline) decreased by ;0.1-0.4 nmol/L (data not shown).
Expt. 2: delayed freezing of serum. Freshly prepared serum samples (n = 21) kept for 2 d at 11°C showed no change in tFOL or 5-methylTHF but showed a small and significant increase in MeFox (0.38 nmol/L) ( Table 3 , Supplemental Fig. 1C, D) . Longer delays in freezing serum samples (7-14 d) resulted in moderate-to-substantial significant decreases in tFOL (2.3-5.1 nmol/L, up to ;10%) and 5-methylTHF (3.4-11.6 nmol/L, up to ;30%) and increases in MeFox (1.82-6.62 nmol/L, up to ;300%). The gain in MeFox only partially compensated for the loss in 5-methylTHF. The decrease in serum folic acid was significant but small (#0.17 nmol/L, ;5%). Serum THF concentrations (0.647 nmol/L at baseline) also decreased by ;0.2-0.3 nmol/L (data not shown).
Expt
at 37°C, but we noted a significant average decrease of ;30% at 24 h (increases of 4.2, 10.8, and 17.0 nmol/L for the low, medium, and high pools, respectively) (Supplemental Table 1 ). MeFox concentrations were fairly stable up to 6 h at room temperature but increased significantly at 24 h by 0.83-2.56 nmol/ L depending on the pool (P-interaction = 0.0072). At 37°C
, MeFox concentrations increased continually with time (e.g., increases of 4.57, 10.5, and 16.3 nmol/L at 24 h for the low, medium, and high pools, respectively; P-interaction = 0.0013). At both temperatures, the molar gain in MeFox was of similar magnitude as the loss in 5-methylTHF at 24 h (Fig. 1) . Serum folic acid and tFOL concentrations were stable under these conditions (small but significant fluctuations in tFOL of #6%).
Expts. 4 and 5: repeated freeze/thaw cycles of serum. We first subjected 3 serum QC pools in closed vials (sample not exposed to air) to up to 3 freeze/thaw cycles. Compared with serum QC pools that were thawed only once, we found no loss of tFOL and 5-methylTHF and only a small but significant increase in folic acid (#1 nmol/L, 5%) after 3 freeze/thaw cycles and significant increases in MeFox (0.12-0.96 nmol/L, up to ;25%) at 1, 2, and 3 freeze/thaw cycles ( Table 4) . Next, we subjected 30 pooled serum samples (each pool was generated from several individual samples to provide sufficient volume) to 4 subsequent analyses ( Table 5 ). This resulted in each pooled sample being opened 4 times and exposed to air for 2 h each. Under these conditions we found a small but significant decrease in tFOL (1.4 nmol/L, ;3%) after 3 freeze/thaw cycles and small but significant changes in 5-methylTHF and MeFox at 1, 2, and 3 freeze/thaw cycles. However, the gain in MeFox (#0.3 nmol/L) only partially compensated for the loss in 5-methylTHF (0.9-1.5 nmol/L). We noted small (<0.2 nmol/L) fluctuations in folic acid and THF (significant at 2 and 3 freeze/thaw cycles).
Expts. 6 and 7: long-term storage of serum at suboptimal conditions. When we stored 3 serum QC pools at 220°C for 3, 6, 9, and 12 mo (Table 6) , we observed a continuous and significant decrease in tFOL (4.91%, 8.64%, 10.2%, and 12.2%, respectively; corresponding to 0.7-2.2, 2.0-5.1, and 3.8-7.5 nmol/ L for the low, medium, and high QC pools, respectively) and 5-methylTHF (9.58%, 16.6%, 18.7%, and 20.9%, respectively; corresponding to 1.1-3.0, 3.7-7.1, and 4.7-10 nmol/L for the low, medium, and high QC pools, respectively), irrespective of the folate baseline concentration. We observed a significant increase in MeFox up to 6 mo followed by concentrations reaching a plateau in all 3 QC pools (P-interaction = 0.0299), as follows: low QC: 0.41, 0.82, 0.87, and 0.80 nmol/L or 66.9%, 134%, 142%, and 131%, respectively; medium QC: 1.59, 2.04, 1.94, and 2.01 nmol/ L or 187%, 239%, 227%, and 235%, respectively; and high QC: 1.19, 2.80, 2.67, and 2.54 nmol/L or 63%, 148%, 141%, and 134%, respectively. The molar gain in MeFox made up only a fraction of the loss in 5-methylTHF. Serum folic acid concentrations did not change over the 12-mo storage period. Storing serum at 5°C for 6 and 12 mo (Supplemental Table 2 ) led to significant and drastic changes: approximately half and two-thirds of tFOL was lost and approximately three-fourths and almost all of the 5-methylTHF was lost, respectively. Even though MeFox concentrations nearly quadrupled after 6 mo, the gain in MeFox only compensated for a small fraction of the loss in 5-methylTHF. Under these drastic storage conditions we also found a significant but small decrease in serum folic acid at 12 mo (6.61%). 
Discussion
The present study investigated changes in serum folate forms in response to a series of suboptimal preanalytical experiments on folate stability, covering the full spectrum from whole blood processing to repeated freeze/thaw cycles of samples as part of the laboratory analysis. Because 5-methylTHF makes up the major portion of circulating folates (10) and is susceptible to oxidative degradation to MeFox (11), a folate form that is detected in most serum samples (6) but is biologically inactive (12) , it is critical to understand how these 2 folate forms behave under preanalytical conditions. Folic acid is another important component in serum samples, especially in populations who are exposed to folic acidfortified foods (10) , but this vitamer is generally believed to have good stability (2, 13) . Not much is known about the stability of minor folate forms (THF, 5-formylTHF, and 5,10-methenylTHF) during suboptimal preanalytical conditions, particularly because these vitamers are present in serum at low concentrations and often not detectable. However, during analysis, these folates are known to be either sensitive to oxidation or subject to interconversions (2,13).
The notable loss of 5-methylTHF during delayed processing of whole blood, 14.5 nmol/L (36%) after only 1 d at 32°C, was similar to the loss of tFOL (12.9 nmol/L or 30%) we reported earlier from the microbiologic assay for the same set of samples (7) . This is expected because the microbiologic assay does not respond to MeFox. The tFOL measured by our HPLC-MS/MS included MeFox and as a result decreased by only 5.5 nmol/L (11%). A previous report on a 1-d serum-clot contact time at 32°C reported only a 15% loss of tFOL measured by radioimmunoassay (14) . This brings up the question of whether the latter assay may have responded to MeFox and emphasizes that findings obtained with 1 method have to be carefully interpreted and cannot necessarily be applied to another. In addition, more research is needed to investigate whether different clinical folate assays respond to MeFox.
As expected, the loss of 5-methylTHF was more moderate when serum was stored at 11°C (3.4, 5.7, and 11.6 nmol/L after 7, 10, and 14 d, respectively) and similar to the loss of tFOL (1.9, 4.0, and 10.6 nmol/L) that we reported earlier from the 1 A duration of 2 h per F/T cycle at 22°C was used. Serum QC pools stored at 270°C were used as a reference. Statistical analysis was by 2-factor ANOVA. *0.0001 $ P , 0.05, **P , 0.0001. F/T, freeze/thaw cycle; MeFox, pyrazino-s-triazine derivative of 4a-hydroxy-5-methyltetrahydrofolate; QC, quality control; tFOL, total folate; 5-methylTHF, 5-methyltetrahydrofolate. 2 Values are geometric means from 4 replicates/condition. 3 Values are percentage changes (95% CIs) compared with reference across the QC pools (no significant interaction between time and pool). 1 Pooled serum samples were subjected to 3 F/T cycles (2 h/cycle at 22°C) beyond the first thaw to produce a total of 4 results; the first result was used as a reference. Statistical analysis was by 1-factor repeated-measures ANOVA. *0.0001 $ P , 0.05, **P , 0.0001. F/T, freeze/thaw cycle; MeFox, pyrazino-s-triazine derivative of 4a-hydroxy-5-methyltetrahydrofolate; tFOL, total folate; 5-methylTHF, 5-methyltetrahydrofolate. 2 Values are geometric means (95% CIs); n = 30. 3 Values are percentage changes (95% CIs) compared with reference.
Serum folate stability 1877 microbiologic assay (7) . However, the large increase in MeFox (1.82-6.62 nmol/L when serum was stored 7-14 d at 11°C and 7.17-8.63 nmol/L when unprocessed whole blood was stored 1-3 d at 32°C) did not compensate for the loss of 5-methylTHF. This means that although capturing MeFox as part of tFOL is important, it does not guarantee that all folate that was originally in the sample is accounted for. Following proper preanalytical conditions that protect labile folates is still important.
Although the room temperature condition in our experiment on short-term exposure of serum to elevated temperature was similar to the kinetic study conducted by Hannisdal et al. (4) and confirmed their findings [5-methylTHF was stable at room temperature for 24 h (our study) and 48 h (4)], the 37°C condition was new and added to the previous findings [33% loss of 5-methylTHF after 1 d at 37°C (our study) vs. 50% loss of 5-methylTHF after 8 d at room temperature (4)]. Our observation that the 5-methylTHF loss after 1 d at either room temperature or 37°C was recovered by MeFox was similar to the conclusion by Hannisdal et al. (4) that the 5-methylTHF loss within 2 d at room temperature was recovered by MeFox. This indicates that a limited exposure of serum to moderate temperature does not compromise the quantitation of tFOL as long as MeFox is also measured as part of the tFOL.
The stability of folates during repeated freeze/thaw cycles of serum is of great concern because analyses sometimes have to be repeated due to an analysis being out of control or specific results violating predetermined sample QC criteria. We confirmed previous findings that folates are relatively stable (<5% loss) when exposed to a limited number of short freeze/thaw cycles. Pfeiffer et al. (9) found no loss of folates when serum was briefly (1 h) subjected to 3 freeze/thaw cycles at room temperature but found some folate loss (;10%) when samples were kept at room temperature for an extended time (5 h). Similarly, Drammeh et al. (7) found some folate loss (<5%) when serum was subjected to 3 freeze/thaw cycles. The moderate increase in MeFox (<1 nmol/L) in the absence of a loss of 5-methylTHF that we observed in the ''closed vial'' Expt. 4 may be due to the structural rearrangement of residual 4a-hydroxy-5-methylTHF (the intermediary product in the oxidation of 5-methylTHF) to MeFox.
Only sparse information is available on long-term storage stability of folates (15) , particularly at suboptimal temperatures, which is the case if the laboratory does not have access to a lowtemperature freezer. Good stability of folates in serum or plasma containing ascorbic acid (5 g/L) stored at 220°C for years was reported (16) . On the other hand, a 20% decrease in folate was noted in serum samples (without added ascorbic acid) stored at 220°C for 1 y with no further decrease thereafter for up to 4 y (17). This was similar to our finding of a 21% loss of 5-methylTHF when we stored serum QC samples (without added ascorbic acid) at 220°C for 1 y. One study reported an even higher (40%) loss of folate after serum storage at 220°C for 1 mo, but concentrations remained stable afterward for 1 y (18) . The doubling to tripling of MeFox concentrations in our Expt. 6 (serum storage at 220°C for 1 y) was not able to compensate for the molar loss of 5-methylTHF and confirmed findings by Hannisdal et al. (5) who investigated the analytical recovery of folate and its degradation products during long-term storage of serum at 225°C for up to 29 y. Although the authors found MeFox in all specimens, this oxidation product did not compensate for the complete loss of folate; substantial folate degradation was recovered as para-aminobenzoylglutamate. Not surprisingly, we found drastic 5-methylTHF losses when serum was stored at 5°C for up to 1 y, yet only 7% loss of folic acid. Folic acid showed good stability during frozen storage at 220°C for 1 y but also during most other preanalytical experiments in our study.
Our study has several strengths. We covered a broad range of preanalytical conditions, including some extreme conditions that are rarely reported in the literature. The analyses were conducted with a sensitive, specific, and precise HPLC-MS/MS method. To enhance the power of our study, we analyzed either >20 individual samples per condition or several replicates (>4) of the same pool per condition. A limitation of our study is that we did not apply a consistent design to all experiments. This was because we relied on already available and unique sample sets for some experiments (7), whereas for others we relied on wellcharacterized serum QC pools. It would have been desirable to also obtain information on the behavior of minor folate forms; however, this is limited by the fact that in most samples those vitamer forms are not detectable.
In conclusion, the current study provides valuable information for the design of field studies. Our findings reemphasize that sample processing and storage time and temperature are critical variables that influence serum folate stability and the accuracy of results. Prompt processing of whole blood and storage of serum at an optimal temperature (270°C) is critical to prevent the loss of folate and the oxidation of 5-methylTHF to MeFox. Although the quantitation of MeFox in optimally collected, processed, and stored samples is critical to compensate for minor losses of 5-methylTHF during preanalytical steps, MeFox may not completely recover the loss of 5-methylTHF, especially when samples have undergone more extreme suboptimal processing and storage conditions. 
